Drug major Novartis AG on Friday announced a strategic review of Novartis India Ltd, a public company listed on the BSE.
The strategic review will include an assessment of the 70.68% shareholding of Novartis AG in the company, the drug firm said in a statement.
Novartis India Ltd is separate from Novartis Healthcare Pvt Ltd, the wholly owned subsidiary of Novartis group in India.
Novartis Healthcare Pvt Ltd includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country.
The strategic review will not impact Novartis Healthcare Pvt Ltd, Novartis AG stated.
There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said.
Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years, it added.
Novartis employs over 8,100 associates in India.
RECOMMENDED FOR YOU
Bain-Backed Indian Auto Parts Maker Is Said To Consider 2026 IPO
Jul 31, 2025
ED Files Case Against Credit Payment App Company For FDI 'Violation'
Jul 24, 2025
.png?rect=0%2C0%2C3500%2C1969&w=75)
Ceigall India Gets Order Worth Rs 1,199 Crore From NHAI
Jul 01, 2025
Gabriel India Shares Surge 20% To Hit New High After Announcing Restructuring Plan
Jul 01, 2025
POPULAR